Earnings summaries and quarterly performance for CITIUS ONCOLOGY.
Executive leadership at CITIUS ONCOLOGY.
Board of directors at CITIUS ONCOLOGY.
Research analysts covering CITIUS ONCOLOGY.
Recent press releases and 8-K filings for CTOR.
Citius Oncology Closes $18 Million Concurrent Offerings
CTOR
Product Launch
New Projects/Investments
- Citius Oncology (CTOR) closed a registered direct offering and a private placement on December 10, 2025, raising approximately $18 million in gross proceeds.
- The offerings included the sale of common stock and warrants at a purchase price of $1.09 per share.
- The net proceeds are intended to support the commercial launch of LYMPHIR, which was launched in December 2025 and targets an initial market estimated to exceed $400 million, as well as for working capital and general corporate purposes.
- Additionally, existing warrants to purchase 11,961,040 shares issued in July and September 2025 had their exercise prices reduced to $1.09 per share.
Dec 10, 2025, 9:30 PM
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement
CTOR
New Projects/Investments
Product Launch
- Citius Oncology has entered into agreements for a registered direct offering and a concurrent private placement, expecting to raise approximately $18 million in gross proceeds.
- The offerings involve the purchase and sale of common stock and warrants at a price of $1.09 per share, with closing anticipated on or about December 10, 2025.
- The net proceeds are intended to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL), which was launched in December 2025 and has an estimated initial market exceeding $400 million.
- The company also agreed to amend certain existing warrants issued in July and September 2025, reducing their exercise price to $1.09 per share.
Dec 9, 2025, 1:30 PM
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East
CTOR
Product Launch
New Projects/Investments
- Citius Oncology has entered into an exclusive distribution agreement with Er-Kim for its drug LYMPHIR (denileukin diftitox-cxdl).
- This partnership expands LYMPHIR's distribution to Turkey and six Gulf Cooperation Council (GCC) countries: Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.
- The agreement increases LYMPHIR's international availability to a total of 19 markets outside the U.S., with Er-Kim responsible for sales, marketing, and reimbursement activities in these territories.
- LYMPHIR, approved by the U.S. FDA for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, was launched in the U.S. in December 2025.
Dec 4, 2025, 1:37 PM
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR
CTOR
Product Launch
New Projects/Investments
- Citius Oncology announced the U.S. commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) on December 1, 2025.
- LYMPHIR is the company's first marketed product and is approved by the U.S. FDA for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL).
- The estimated U.S. market for LYMPHIR is over $400 million and is growing.
- LYMPHIR is now available nationwide through specialty distributors, supported by a permanent J-code (J9161) effective April 1, 2025, to facilitate reimbursement.
- The company is also pursuing international market access, holding exclusive rights in most global markets and having signed a distribution agreement with Integris Pharma S.A. for Southern European and Balkan countries.
Dec 1, 2025, 10:12 PM
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR
CTOR
Product Launch
New Projects/Investments
- Citius Oncology announced the U.S. commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) on December 1, 2025, a novel cancer immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL).
- LYMPHIR, which received FDA approval in August 2024, is now available nationwide through specialty distributors.
- The company estimates LYMPHIR is entering a growing U.S. market valued at over $400 million.
- A permanent J-code (J9161), effective April 1, 2025, has been assigned to facilitate reimbursement and streamline claims processing.
Dec 1, 2025, 5:00 PM
Citius Oncology to Exhibit LYMPHIR at ASH 2025 Meeting
CTOR
Product Launch
New Projects/Investments
- Citius Oncology will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition from December 6\u20139, 2025, to discuss its approved product, LYMPHIR.
- LYMPHIR (denileukin diftitox-cxdl) received FDA approval in August 2024 for the treatment of adult patients with relapsed or refractory Stage I\u2013III cutaneous T-cell lymphoma (CTCL).
- The launch of LYMPHIR is on track for Q4 2025.
- Management estimates the initial market for LYMPHIR currently exceeds $400 million and is considered underserved.
Nov 25, 2025, 1:00 PM
Citius Oncology to Integrate Verix AI for LYMPHIR Commercial Launch
CTOR
Product Launch
New Projects/Investments
- Citius Oncology is deepening its collaboration with Verix to leverage its Tovana AI platform for the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR.
- LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy, was approved by the FDA in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).
- The Verix Tovana platform will support Citius Oncology's commercial strategy by integrating advanced analytics, real-world claims data, and machine learning to enhance salesforce targeting and engagement with high-impact healthcare providers.
- Management estimates the initial market for LYMPHIR currently exceeds $400 million and is growing.
Nov 21, 2025, 1:37 PM
Citius Oncology Signs U.S. Distribution Agreement with McKesson for LYMPHIR
CTOR
Product Launch
New Projects/Investments
- Citius Oncology, Inc. (CTOR) has finalized a U.S. distribution agreement with McKesson Corporation (MCK) for its FDA-approved immunotherapy, LYMPHIR.
- This agreement completes Citius Oncology's core U.S. distribution network, securing broad access for LYMPHIR's planned commercial launch in the fourth quarter of 2025.
- LYMPHIR, approved in August 2024 for relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL), targets an initial market estimated to exceed $400 million.
Oct 20, 2025, 12:37 PM
Citius Oncology Finalizes Exclusive Commercialization Agreement with EVERSANA for LYMPHIR Launch
CTOR
Product Launch
New Projects/Investments
- Citius Oncology (CTOR) has finalized an exclusive agreement with EVERSANA to support the anticipated Q4 2025 U.S. commercialization of LYMPHIR™.
- LYMPHIR™, an FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), received its approval in August 2024.
- EVERSANA will serve as Citius Oncology's exclusive commercialization partner, providing integrated services including medical information, pharmacovigilance, and revenue cycle management.
- The estimated initial market for LYMPHIR™ exceeds $400 million and is growing.
Oct 16, 2025, 12:47 PM
Citius Oncology Establishes International Access for LYMPHIR in Southern Europe
CTOR
Product Launch
New Projects/Investments
- Citius Oncology (CTOR) has signed an exclusive distribution agreement with Integris Pharma S.A. to provide LYMPHIR™ through Named Patient Programs in Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro, and North Macedonia.
- This initiative expands international access for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) that received FDA approval in August 2024.
- The company is also actively discussing with other potential distribution partners in additional European Union member states, South America, and select Middle Eastern territories to further position LYMPHIR for global growth.
Oct 7, 2025, 12:47 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more